Jazz Pharmaceuticals (NSDQ:JAZZ) said today that the FDA approved its Vyxeos injectable liposome for the treatment of adults with two types of acute myeloid leukemia.
Vyxeos is the first product designed with the Dublin-based company’s CombiPlex technology, delivering a fixed-ratio of daunorubicin and cytarabine to a patient’s bone marrow.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves Jazz Pharmaceutical’s liposomal AML chemotherapy appeared first on MassDevice.